AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33216188 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-bundle anterior cruciate ligament reconstruction (DBR)
Number of subjects: 103
Study 33216188 — intervention group
Group type: COMPARATOR
Intervention: Single-bundle anterior cruciate ligament reconstruction (SBR)
Number of subjects: 103
Study 33216238 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil sublingual tablet system (SSTS) 15 mcg
Number of subjects: 72
Study 33216238 — intervention group
Group type: COMPARATOR
Intervention: Oral oxycodone extended release 10 mg twice daily and oral oxycodone immediate-release 5 mg up to four times daily on demand (Oxy group)
Number of subjects: 72
Study 33216238 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil sublingual tablet system (SSTS)
Number of subjects: 72
Study 33216238 — intervention group
Group type: COMPARATOR
Intervention: Oral oxycodone (Oxy group)
Number of subjects: 72
Study 33216280 — intervention group
Group type: EXPERIMENTAL
Intervention: PAX4 R192H
Number of subjects: 80
Study 33216280 — intervention group
Group type: EXPERIMENTAL
Intervention: PAX4 R192S
Number of subjects: 80
Study 33216287 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous tocilizumab (TCZ-SC) treatment
Number of subjects: 285
Study 33216356 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab and ipilimumab (nivolumab at 3 mg/kg and ipilimumab at 1 mg/kg intravenously every 3 weeks for 4 doses, followed by 480 mg of nivolumab intravenously every 4 weeks)
Number of subjects: 55
Study 33216356 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab and ipilimumab
Number of subjects: 55
Study 33216772 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum apolipoprotein-A1 at 1.25 g/L cutoff
Number of subjects: 232949
Study 33216772 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum apolipoprotein-A1
Number of subjects: 232949
Study 33216879 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/benazepril
Number of subjects: 11506
Study 33216879 — intervention group
Group type: COMPARATOR
Intervention: HCTZ/benazepril
Number of subjects: 11506
Study 33216887 — intervention group
Group type: EXPERIMENTAL
Intervention: Virus-specific T cells (VSTs) against BKPyV
Number of subjects: 41
Study 33217027 — intervention group
Group type: COMPARATOR
Intervention: CSL112 (6 g dosing)
Number of subjects: 0
Study 33217193 — intervention group
Group type: EXPERIMENTAL
Intervention: Any treatment for recurrence
Number of subjects: 1085
Study 33217193 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib therapy
Number of subjects: 1085
Study 33217193 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery/trans-arterial chemoembolization (TACE)
Number of subjects: 1085
Study 33217193 — intervention group
Group type: COMPARATOR
Intervention: Early recurrence
Number of subjects: 1085
Study 33217357 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody treatment (mAB114 or REGN-EB3)
Number of subjects: 2
Study 33217414 — intervention group
Group type: EXPERIMENTAL
Intervention: Women undergoing pulmonary resections for lung cancer
Number of subjects: 6356
Study 33217419 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental cardiopulmonary exercise testing (CPET) at the ventilatory threshold (Tvent)
Number of subjects: 96
Study 33218740 — intervention group
Group type: EXPERIMENTAL
Intervention: Agalsidase alfa treatment
Number of subjects: 560
Study 33218965 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 490
Study 33218965 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 490
Study 33218965 — intervention group
Group type: COMPARATOR
Intervention: Treatment-free interval
Number of subjects: 490
Study 33218965 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing treatment (≥1 year)
Number of subjects: 490
Study 33218965 — intervention group
Group type: COMPARATOR
Intervention: Grade 3/4 toxicity
Number of subjects: 490
Study 33219014 — intervention group
Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec (TVEC) at dose level 1 (DL 1 = 10) combined with neoadjuvant chemotherapy (NAC)
Number of subjects: 9
Study 33219014 — intervention group
Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec (TVEC) at dose level 2 (DL 2) combined with neoadjuvant chemotherapy (NAC)
Number of subjects: 9
Study 33219092 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab (programmed death ligand 1 inhibitor)
Number of subjects: 1783
Study 33219118 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial frequency domain imaging (SFDI)
Number of subjects: 35
Study 33219145 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletal muscle MRI and proton magnetic resonance spectroscopy
Number of subjects: 31
Study 33219145 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletal muscle MRI
Number of subjects: 31
Study 33219433 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental exhaustive bout of exercise
Number of subjects: 22
Study 33219433 — intervention group
Group type: COMPARATOR
Intervention: Type 1 diabetes participants
Number of subjects: 22
Study 33219460 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 256
Study 33219463 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress myocardial perfusion entropy (MPE)
Number of subjects: 166
Study 33219463 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress perfusion defect (SSS≥4)
Number of subjects: 166
Study 33219935 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral adiposity index (VAI)
Number of subjects: 3363
Study 33219986 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-nickel diet for 8 weeks
Number of subjects: 20
Study 33220319 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy
Number of subjects: 373
Study 33220319 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy children)
Number of subjects: 373
Study 33220762 — intervention group
Group type: COMPARATOR
Intervention: High adherence to the Mediterranean lifestyle index (>14 points)
Number of subjects: 20494
Study 33220762 — intervention group
Group type: COMPARATOR
Intervention: Each additional point in Mediterranean lifestyle index
Number of subjects: 20494
Study 33220762 — intervention group
Group type: COMPARATOR
Intervention: High adherence to Mediterranean lifestyle index among participants aged ≥50 years
Number of subjects: 20494
Study 33220762 — intervention group
Group type: COMPARATOR
Intervention: High adherence to Mediterranean lifestyle index among participants aged <50 years
Number of subjects: 20494
Study 33221175 — intervention group
Group type: EXPERIMENTAL
Intervention: Telisotuzumab vedotin 2.7 mg/kg administered intravenously every 3 weeks until disease progression or unacceptable toxicity
Number of subjects: 28
Study 33221175 — intervention group
Group type: EXPERIMENTAL
Intervention: Telisotuzumab vedotin
Number of subjects: 28
Study 33221216 — intervention group
Group type: EXPERIMENTAL
Intervention: High Calcified Plaque Volume (CPV)
Number of subjects: 925
Study 33221216 — intervention group
Group type: EXPERIMENTAL
Intervention: High Percent Calcified Plaque Volume (PCPV)
Number of subjects: 925
Study 33221224 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT/CT imaging
Number of subjects: 25
Study 33221242 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance (CMR) with tagging
Number of subjects: 79
Study 33221242 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic age-matched controls
Number of subjects: 79
Study 33221715 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifrontal transcranial direct current stimulation (tDCS) applied using a 2 mA current for 20 min, twice daily, for 5 consecutive weekdays.
Number of subjects: 80
Study 33221715 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifrontal transcranial direct current stimulation (tDCS)
Number of subjects: 80
Study 33221907 — intervention group
Group type: EXPERIMENTAL
Intervention: Familial chylomicronemia syndrome (FCS)
Number of subjects: 29
Study 33221907 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial chylomicronemia syndrome (MCS)
Number of subjects: 29
Study 33221921 — intervention group
Group type: EXPERIMENTAL
Intervention: 11C-MET PET-CT
Number of subjects: 12
Study 33221921 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET-CT
Number of subjects: 12
Study 33221921 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 12
Study 33221921 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical assessments and labial salivary gland biopsies
Number of subjects: 12
Study 33221921 — intervention group
Group type: EXPERIMENTAL
Intervention: 11C-MET uptake in lacrimal gland
Number of subjects: 12
Study 33221921 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-FDG uptake in parotid gland
Number of subjects: 12
Study 33222307 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma-specific upper-airway microbiome composition (decreased ratio of Patescibacteria/Actinobacteria)
Number of subjects: 133
Study 33222307 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent sweet consumption (≥ 7/week)
Number of subjects: 133
Study 33222307 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced biodiversity
Number of subjects: 133
Study 33222307 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of Staphylococcus strains in the nasopharynx
Number of subjects: 133
Study 33222307 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower expression of beta-defensin 2, IL-5, and IL-13 in the nasal mucosa
Number of subjects: 133
Study 33222307 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent antibiotic use
Number of subjects: 133
Study 33222307 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher nasal expression of IL-17 and T1R3 (sweet taste receptor)
Number of subjects: 133
Study 33222307 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced sweet taste perception
Number of subjects: 133
Study 33222379 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbapenem monotherapy (primarily meropenem)
Number of subjects: 306
Study 33222379 — intervention group
Group type: EXPERIMENTAL
Intervention: BLBLI monotherapy (mostly piperacillin-tazobactam)
Number of subjects: 306
Study 33222379 — intervention group
Group type: COMPARATOR
Intervention: Any active therapy (including BLBLI and carbapenem)
Number of subjects: 306
Study 33222617 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (MT)
Number of subjects: 93
Study 33222803 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tenofovir disoproxil fumarate and emtricitabine for PrEP, taken daily for the first 12 weeks.
Number of subjects: 148
Study 33223114 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary infections (BSIs and pLRTIs)
Number of subjects: 731
Study 33223114 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall incidence of secondary infections
Number of subjects: 731
Study 33223114 — intervention group
Group type: EXPERIMENTAL
Intervention: Types of pathogens causing BSIs
Number of subjects: 731
Study 33223114 — intervention group
Group type: EXPERIMENTAL
Intervention: Types of pathogens causing pLRTIs
Number of subjects: 731
Study 33223114 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for secondary infections
Number of subjects: 731
Study 33224623 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET/CT imaging
Number of subjects: 33
Study 33224628 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR439459 (pan-TGFβ neutralizing antibody)
Number of subjects: 0
Study 33224628 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of SAR439459 with anti-PD-1
Number of subjects: 0
Study 33224628 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR439459
Number of subjects: 0
Study 33224753 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (once daily)
Number of subjects: 271
Study 33224753 — intervention group
Group type: COMPARATOR
Intervention: Dabigatran (twice daily)
Number of subjects: 271
Study 33224806 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone (treatment group, n=41)
Number of subjects: 81
Study 33224806 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group, n=40)
Number of subjects: 81
Study 33225383 — intervention group
Group type: EXPERIMENTAL
Intervention: Living in an institution
Number of subjects: 987
Study 33225383 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired Activity of Daily Living scale score
Number of subjects: 987
Study 33225383 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c ≥ 70 mmol/mol
Number of subjects: 987
Study 33225410 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethyl fumarate (DMF) 240 mg twice daily
Number of subjects: 231
Study 33225717 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose intake during an oral glucose tolerance test, assessed by indirect calorimetry for measuring diet-induced thermogenesis (DIT).
Number of subjects: 17
Study 33225717 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold exposure for 2 hours to assess cold-induced thermogenesis (CIT).
Number of subjects: 17
Study 33225717 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of maximum brown adipose tissue (BAT) activity using 18-F-fluoro-deoxyglucose.
Number of subjects: 17
Study 33225826 — intervention group
Group type: EXPERIMENTAL
Intervention: Cordycepin
Number of subjects: 0
Study 33225915 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Together (HT) program
Number of subjects: 663
Study 33225917 — intervention group
Group type: EXPERIMENTAL
Intervention: Home haemodialysis (HHD)
Number of subjects: 160
Study 33225917 — intervention group
Group type: COMPARATOR
Intervention: Conventional in-centre haemodialysis (ICHD)
Number of subjects: 160
Study 33225952 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose thromboprophylaxis (≥ 175 IU/kg of body weight tinzaparin or ≥ 200 IU/kg of body weight dalteparin)
Number of subjects: 152
Study 33225952 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose thromboprophylaxis (> 4500 IU but < 175 IU/kg of body weight tinzaparin or > 5000 IU but < 200 IU/kg of body weight dalteparin)
Number of subjects: 152
Study 33225952 — intervention group
Group type: COMPARATOR
Intervention: Low-dose thromboprophylaxis (2500-4500 IU tinzaparin or 2500-5000 IU dalteparin)
Number of subjects: 152
Study 33225952 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose thromboprophylaxis
Number of subjects: 152
Study 33225952 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose thromboprophylaxis
Number of subjects: 152
Study 33225952 — intervention group
Group type: COMPARATOR
Intervention: Low-dose thromboprophylaxis
Number of subjects: 152
Study 33226334 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid use (measured in lowest recommended dosage units)
Number of subjects: 65
Study 33226334 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep parameters (actigraphy/self-reported total wake time and self-reported sleep quality)
Number of subjects: 65
Study 33226334 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening pain
Number of subjects: 65
Study 33226548 — intervention group
Group type: EXPERIMENTAL
Intervention: DAILY EATS questionnaire
Number of subjects: 0
Study 33226548 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating Drivers Index (EDI) derived from DAILY EATS items
Number of subjects: 0
Study 33226632 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized fortification (targeted or adjustable)
Number of subjects: 521
Study 33226632 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted fortification
Number of subjects: 521
Study 33226632 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustable fortification
Number of subjects: 521
Study 33226632 — intervention group
Group type: COMPARATOR
Intervention: Standard non-individualized fortification
Number of subjects: 521
Study 33227125 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg/d
Number of subjects: 63
Study 33227125 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg/d (prior RTX treatment)
Number of subjects: 63
Study 33227125 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg/d (prior RTX-CIT treatment)
Number of subjects: 63
Study 33227125 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg/d (extranodal subtype)
Number of subjects: 63
Study 33227125 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg/d (nodal subtype)
Number of subjects: 63
Study 33227125 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg/d (splenic subtype)
Number of subjects: 63
Study 33227153 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive haemoglobin measurement
Number of subjects: 0
Study 33227283 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopurines (n=242)
Number of subjects: 1490
Study 33227283 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologics (n=642)
Number of subjects: 1490
Study 33227283 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (n=227)
Number of subjects: 1490
Study 33227283 — intervention group
Group type: COMPARATOR
Intervention: Unexposed (n=379)
Number of subjects: 1490
Study 33227283 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher disease activity
Number of subjects: 1490
Study 33227350 — intervention group
Group type: EXPERIMENTAL
Intervention: Proven bacterial infections
Number of subjects: 1273
Study 33227350 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe alcoholic hepatitis
Number of subjects: 1273
Study 33227350 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate first-line antibiotic treatment of proven bacterial infections
Number of subjects: 1273
Study 33227350 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of precipitants
Number of subjects: 1273
Study 33227397 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinicians often wondering about the appropriateness of a resuscitation attempt
Number of subjects: 5099
Study 33227397 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinicians experiencing moral distress caused by inappropriate CPR
Number of subjects: 5099
Study 33227397 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinicians aged 30-44 years
Number of subjects: 5099
Study 33227397 — intervention group
Group type: COMPARATOR
Intervention: Clinicians feeling valued by the team
Number of subjects: 5099
Study 33227397 — intervention group
Group type: COMPARATOR
Intervention: Clinicians in teams where the team leader acknowledged efforts
Number of subjects: 5099
Study 33227397 — intervention group
Group type: COMPARATOR
Intervention: Clinicians in teams that took time for debriefing
Number of subjects: 5099
Study 33228537 — intervention group
Group type: EXPERIMENTAL
Intervention: mTBI patients with APTH
Number of subjects: 77
Study 33228537 — intervention group
Group type: EXPERIMENTAL
Intervention: mTBI patients developing chronic posttraumatic headache (CPTH)
Number of subjects: 77
Study 33228537 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 77
Study 33228724 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy HEI-total
Number of subjects: 0
Study 33228724 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum HEI-total
Number of subjects: 0
Study 33228771 — intervention group
Group type: EXPERIMENTAL
Intervention: Home birth fecal supernatants
Number of subjects: 180
Study 33228771 — intervention group
Group type: COMPARATOR
Intervention: C-section infants
Number of subjects: 180
Study 33228796 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver's relationship to the patient (more parents were the caregiver in females than in males)
Number of subjects: 333
Study 33228796 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver's employment situation (more employed caregivers in females)
Number of subjects: 333
Study 33228796 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic situation of patients
Number of subjects: 333
Study 33228796 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support perception
Number of subjects: 333
Study 33228796 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner relationship perception
Number of subjects: 333
Study 33228796 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional status of families
Number of subjects: 333
Study 33228797 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglustat (part of routine clinical care)
Number of subjects: 36
Study 33228797 — intervention group
Group type: COMPARATOR
Intervention: NPC population
Number of subjects: 36
Study 33228797 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-domain NPCCSS
Number of subjects: 36
Study 33228978 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in plasma tau from preoperative concentrations to postoperative Day 1
Number of subjects: 114
Study 33228978 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in tau
Number of subjects: 114
Study 33228978 — intervention group
Group type: EXPERIMENTAL
Intervention: Tau changes
Number of subjects: 114
Study 33228978 — intervention group
Group type: EXPERIMENTAL
Intervention: Tau
Number of subjects: 114
Study 33229343 — intervention group
Group type: EXPERIMENTAL
Intervention: Convolutional Neural Network (CNN1) for classification of B-scans containing retinal cavitations
Number of subjects: 67
Study 33229343 — intervention group
Group type: EXPERIMENTAL
Intervention: Convolutional Neural Network (CNN2) for segmentation of retinal cavitations
Number of subjects: 67
Study 33229343 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed method for measuring retinal cavitation volume
Number of subjects: 67
Study 33229362 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilonacept 320 mg SC load/160 mg SC weekly maintenance
Number of subjects: 25
Study 33229456 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3300054 monotherapy
Number of subjects: 4
Study 33229456 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3300054 combined with ramucirumab
Number of subjects: 4
Study 33229456 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3300054 combined with abemaciclib
Number of subjects: 4
Study 33229456 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3300054 combined with merestinib
Number of subjects: 4
Study 33229508 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded CD4 T cells cultured with high dose of interleukin-2 for up to 5 weeks
Number of subjects: 23
Study 33229508 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded CD4 T cells with TIM-3 expression
Number of subjects: 23
Study 33229715 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention
Number of subjects: 320
Study 33229715 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-bearing walking training (Kunming Locomotion Training Program - KLTP) for 6 months
Number of subjects: 320